Edgewise Announces Positive EDG-5506 4-Month Interim ARCH Data in BMD

On Sept. 12, 2022, Edgewise Therapeutics released positive 4-month interim data from their open label study in individuals with Becker muscular dystrophy.

Read their full press release below.


Experience the magic of camp promise

Applications open for campers and volunteers!